Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
31 May 2023 - 10:30PM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage
biopharmaceutical company, today announced that Richard A. Miller,
M.D., president and chief executive officer of Corvus, will conduct
one-on-one meetings with investors and present a corporate overview
at the Jefferies Healthcare Conference, which is being held in
New York from June 7-9. The presentation will be on Wednesday,
June 7, 2023 at 9:30 am ET.
A webcast of the presentation will be available live and for 90
days following the event. The webcast may be accessed via the
investor relations section of the Corvus website.
About Corvus PharmaceuticalsCorvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
pioneering the development of ITK inhibition as a new approach to
immunotherapy for a broad range of cancer and immune diseases. The
Company’s lead product candidate is CPI-818, an investigational,
oral, small molecule drug that selectively inhibits ITK and is in a
mid-stage clinical trial for patients with T cell lymphoma. Its
other clinical-stage candidates are being developed for a variety
of cancer indications. For more information,
visit www.corvuspharma.com.
INVESTOR CONTACT:Leiv LeaChief Financial
OfficerCorvus Pharmaceuticals,
Inc.+1-650-900-4522llea@corvuspharma.com
MEDIA CONTACT:Sheryl SeapyReal
Chemistry+1-949-903-4750sseapy@realchemistry.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Jan 2024 to Jan 2025